TG Therapeutics Inc

TGTX

Market Cap$2.69B

Close$

Compare TG Therapeutics

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
TG Therapeutics Inc	64.7	0%	26%	16.5	0.6
Market Avg	53.2	1.27%	29%	-	1.3
Healthcare Avg	29.7	1.32%	16%	7.3	1.3

$49.00

Target Price by Analysts

197.3% upsideTG Therapeutics Target Price Details

$16.18

Current Fair Value

1.8% downside

Overvalued by 1.8% based on the discounted cash flow analysis.

Share Statistics

Market cap	$2.69 Billion
Enterprise Value	$2.58 Billion
Dividend Yield	$0.0 (0.0%)
Earnings per Share	$0.28
Beta	1.35
Outstanding Shares	154,542,945
Avg 30 Day Volume	4,431,674

Return

Return on Equity	-
Return on Assets	-
Return on Invested Capital	-

Valuation & Multiples

P/E Ratio	64.74
PEG	-89.03
Price to Sales	16.48
Price to Book Ratio	16.48
Enterprise Value to Revenue	8.93
Enterprise Value to EBIT	53.43
Enterprise Value to Net Income	62
Total Debt to Enterprise	0.04
Debt to Equity	0.63

Revenue Sources

No data

ESG Score

No data

About TG Therapeutics Inc

CEO: Michael Weiss